Table 4.

Absorbed dose per administered activity for [²²⁵Ac]Ac-DOTA-JR11 and [¹⁷⁷Lu]Lu-DOTA-JR11

Target organ (rt)	d(rt) [mGy/kBq [225Ac]Ac-DOTA-JR11]	d(rt) [mGy/MBq [177Lu]Lu-DOTA-JR11]
Intestines	40.3	23.4
Stomach Wall	137.2	48.8
Heart	11.2	1.9
Kidneys	952.6	406.9
Liver	271.4	38.5
Lungs	37.2	37.7
Pancreas	284.4	120.8
Skeleton	0.1	2.8
Spleen	76.4	8.4
Total Body	44.0	12.6
Tumor (150 mg)	328.5	464.4
T/K ratioa	0.35	1.14

The alpha-contribution to the absorbed dose by [²²⁵Ac]Ac-DOTA-JR11 were weighted with an RBE = 5. The last row indicates the tumor/kidney absorbed dose ratio

^aTumor-to-kidney ratio